Возможности и перспективы Лодоза в леченииизолированной систолической артериальнойгипертензии

1. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969–78.
2. Чазова И.Е., Бойцов С.А., Небиеридзе Д.В. Основные положения проекта второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскул. тер. и профилак. 2004; 4: 90–8.
3. Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Методическое письмо МЗ РФ. М., 2004; 47.
4. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hyperstension: a critical review. J Clin Hypertension 1987; 3: 278–93.
5. Papdemetriou V, Prisant LM, Weber M et al. Low-dose combination therapy in the management of hypertension. Primary Cardiol 1995; 21: 29–31, 39.
6. Prisant LM, Weir MR, Papademetriou V et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–66.
7. PA van Zweiten, Beneficial combinations of two or more antihypertensive drugs, European Society of Hypertension Scientific Newsletter; 2003; 4 (16).
8. Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423–30.
9. Delerme S. Amelioration pression-independante de la distensibilite des gros troncs arteriels par le traitement anti-hypertenseur (DEA de pharmacologie experimental et clinique). Paris: Universite Paris XI; 1997–1998.
10. Asmar R, Hugues C, Pannier B et al. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. Eur Heart J 1987; 8: 115–20.
11. Benetos A, Consoli S, Safavian A et al. Efficacy, safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140 (4): E11.
12. Beevers DG. The end of blockers for uncomplicated hypertension? Lancet 2005; DOI: 1.
13. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choise in the treatment of primary hypertension? A meta-analysis. Lancet 2005; DOI:10.1016/S0140-6736(05) 67573-3.
15. Cruikshank JM. The clinical importance of cardioselectivity and lipophilicity in beta-blockers. Am Heart J 1980; 100: 160–78.
16. Zillich AJ, Garg J, Basu S, Bakris GL et al. Thiazide Diuretics, Potassium, and the Development of Diabetes. A Quantitative Review. Hypertension 2006; 48 (2): 219–24.
17. Dequattro V, Weir MR. Bisoprolol fumarate/hydrochlorothiazide 6,25 mg: a new low dose option for first-line antihypertensive therapy. Adv Ther 1993; 10: 197–206.
18. Frishman WH, Bbryzinksi BS, Coulson LR et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461–8.
19. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
20. Lewin AJ, Leug MC, Targum S et al. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6,25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993; 16: 732–6.
21. Neutel JM, Rolf CN, Valentine SN et al. Low-dose combination therapy as first line treatment of mild to moderate hypertension: the efficacy and safety of bisoprolol/6,25 HCTZ versus amlodipine, enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33–45.
22. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326: 1427.

С.В.Недогода